Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

Charlotte EJ Downes; Barbara J McClure; Benjamin T. Mayne; John B Bruning; Susan L Heatley; Chung Kok; Timothy P Hughes; David T Yeung; Deborah L White

Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

Charlotte EJ Downes
, Barbara J McClure
, Benjamin T. Mayne
, John B Bruning
, Susan L Heatley
, Chung Kok
, Timothy P Hughes
, David T Yeung
, Deborah L White

Research output: Contribution to conference › Poster

Abstract

We modelled and characterised rux resistance in JAK2r B-ALL in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.

Original language	English
Number of pages	1
Publication status	Published - 2018
Externally published	Yes
Event	South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting 2018 - Adelaide, Australia Duration: 25 Oct 2018 → …

Conference

Conference	South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting 2018
Abbreviated title	SAHMRI Annual Scientific Meeting 2018
Country/Territory	Australia
City	Adelaide
Period	25/10/18 → …

Keywords

Identification
Ruxolitinib
Resistant Mutations

Precision medicine approaches for JAK2-rearranged ALL: The efficacy of targeted therapies and molecular mechanisms of drug resistance
Toomes, C. (Associate Investigator), White, D. L. (Chief Investigator (Project Lead)), McClure, B. (Associate Investigator) & Bruning, J. B. (Associate Investigator)
12/03/18 → 31/12/22
Project: Research

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
Downes, C. E. J., McClure, B. J., Bruning, J. B., Page, E., Breen, J., Rehn, J., Yeung, D. T. & White, D. L., 10 Aug 2021, In: npj Precision Oncology. 5, 13 p., 75.
Research output: Contribution to journal › Article › peer-review

Open Access
File
21 Citations (Scopus)

64 Downloads (Pure)

Cite this

Downes, C. EJ., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., Hughes, T. P., Yeung, D. T., & White, D. L. (2018). Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting 2018, Adelaide, South Australia, Australia.

@conference{11f4c356a82f46a29906ba2051581e70,

title = "Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion",

abstract = "We modelled and characterised rux resistance in JAK2r B-ALL in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.",

keywords = "Identification, Ruxolitinib, Resistant Mutations",

author = "Downes, \{Charlotte EJ\} and McClure, \{Barbara J\} and Mayne, \{Benjamin T.\} and Bruning, \{John B\} and Heatley, \{Susan L\} and Chung Kok and Hughes, \{Timothy P\} and Yeung, \{David T\} and White, \{Deborah L\}",

year = "2018",

language = "English",

note = "South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting 2018, SAHMRI Annual Scientific Meeting 2018 ; Conference date: 25-10-2018",

}

Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. / Downes, Charlotte EJ; McClure, Barbara J; Mayne, Benjamin T. et al.
2018. Poster session presented at South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting 2018, Adelaide, South Australia, Australia.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

AU - Downes, Charlotte EJ

AU - McClure, Barbara J

AU - Mayne, Benjamin T.

AU - Bruning, John B

AU - Heatley, Susan L

AU - Kok, Chung

AU - Hughes, Timothy P

AU - Yeung, David T

AU - White, Deborah L

PY - 2018

Y1 - 2018

N2 - We modelled and characterised rux resistance in JAK2r B-ALL in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.

AB - We modelled and characterised rux resistance in JAK2r B-ALL in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.

KW - Identification

KW - Ruxolitinib

KW - Resistant Mutations

M3 - Poster

T2 - South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting 2018

Y2 - 25 October 2018

ER -

Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

Abstract

Conference

Keywords

Fingerprint

Projects

Precision medicine approaches for JAK2-rearranged ALL: The efficacy of targeted therapies and molecular mechanisms of drug resistance

Research output

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

Cite this